Skip to content
drillr.ai

OTLK

Outlook Therapeutics, Inc.

NASDAQ · USHealthcareBiotechnology
$1.38-0.72%

Price as of Jul 20, 2026

OTLK news

Outlook Therapeutics, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD

    ISELIN, N.J., June 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (https://www.globenewswire.com/Tracker?data=9945MzUs41eabzIabJnYh5CBADTPYamlUOYj5GE0LL56UHq16pd9QqXXA-g7HF4E7rnufYDyBStlrI8k5f9LM5WUPbwpZvXNjrrARqaVBcMTWwMeNAM27761a-HU9MKl) (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the resubmission of the

    Globe Newswire ·

  2. Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

    ISELIN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (https://www.globenewswire.com/Tracker?data=LaA08SCErPilWM8O6jp1LSp2ts7LKot0RrTzJqCW3R9xHTwPfh0xU4mzmZJs5cCjmKwMWt2Nua__8gdRvijhsIwfwadSvMSX2KWVD74KW1VBVSTu4_brQoNu0G1swtCi) (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced the resubmission of its Biologics License A

    Globe Newswire ·

  3. Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

    ISELIN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (https://www.globenewswire.com/Tracker?data=n6BjhMS1GWlp7Pqr42Rm7kWQTaEor58bib0I9JCOK3Y2iJQ4txKqnesR02DrOepZjeDT8ZpAU7YBJwI1CKBKKK7Ywm5S7gZh_CQ-OANDZvCBFytJnLW_1fFew2X1yBRa) (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that it has entered into a definitive agreem

    Globe Newswire ·

  4. Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

    * Completed Formal Dispute Resolution Meeting with FDA regarding Complete Response Letter (CRL) for ONS-5010; Decision Expected This Month * Continued expansion of LYTENAVA™ (bevacizumab gamma) in Europe with Commercial Distribution Agreement with Mediconsult AG in Switzerland * Launched Real-World Evidence Study in Germany to Further Strengthen the Overall Value Proposition of LYTENAVA™ ISELIN, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (https://www.globenewswire.com/Tra

    Globe Newswire ·

  5. Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering

    ISELIN, N.J., April 23, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (https://www.globenewswire.com/Tracker?data=q4evvZyKkL5NTyhARjwjyYsXQlxEPQaAPHv0QhhYRJJLVH9ooVT2Qwg819Z2l0KKij4spHBWVh7o-onSqQsGuqVM29jX8GWkTYBtCpS--wOLbuov9YfSiVLd16nikEvp) (Nasdaq: OTLK) (“Outlook Therapeutics” or the “Company”), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the closing of its previously announced registered d

    Globe Newswire ·

  6. Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

    ISELIN, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (https://www.globenewswire.com/Tracker?data=agZUG193MufKEAKQyCtohXhqLIchOgIEDCTex-SUwqOsSFyz4MpOkKpHLAPUiYEN7oN_Vf9pxu5tfLffpk4l6j8RdsNKH7yQLGj7xbeDy-cjv6aIH2tvsGpR9aSjcBUm) (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has completed its Federal Dispute Resolution meeting with the Office of New Drugs at t

    Globe Newswire ·

  7. Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA

    ISELIN, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (https://www.globenewswire.com/Tracker?data=vUIjEkLNjLejEPXr9Yj1j9_cbz2xTdJd61JMLnFEC1HjAEtrtyRU6gW0a2I-0IQj-L-UbELvjPURzkmrqUh7wDhAlQZhkYMjp9vuRtJAkmlDzOuETWk3NBMqFkrc8BYh) (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it submitted a formal dispute resolution request (FDRR) to the U.S. Food and Drug Adminis

    Globe Newswire ·

  8. Outlook Therapeutics Announces Closing of $5.0 Million Public Offering

    ISELIN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (https://www.globenewswire.com/Tracker?data=OBmf_ZhjYmMtEIG8pWe74ETOI2GGJuPwcNzCAgAKLgzylXn8RSlvSI2-nZpE06J37mOvWm1hOzYq3TdhMteRnQ3_4psOVr_MlTDFhfAOpibqfSqA4Q-BsdsSijYjMYCS) (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the closing of its previously announced public offering of 20,000,000 shares of its common sto

    Globe Newswire ·

  9. Outlook Therapeutics Announces Proposed Public Offering

    ISELIN, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (https://www.globenewswire.com/Tracker?data=zg3CAJrYCmQdl9wX8xyo2GLlXFnEOFq24d1U6AF2NW6k3YFh_bfOsk_Tv4PRbDtM2-QpsgHqvurfw7LKRk5aGZfLlphmHhJpgmA0G9TilpL0RLZo1WhruQmudbC0xrE5) (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced a best-efforts public offering of its common stock (or pre-funded warran

    Globe Newswire ·

  10. Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note

    ISELIN, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (https://www.globenewswire.com/Tracker?data=-HavFWdyTY1e3vhX0KRJ77yC1kUiOGGjRY5Ew8fhgg4yAnXzEIaPkKBLygS1xAJ_cSoDSo9UDo-1xx3RTH0ffWPeL_Uk0QyX3ChLurD_tRuQMSPV1p5-fc4RcreCVOCM) (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced an amendment to its existing convertible note with Avondale Capital, LLC (the “Existing Note”)

    Globe Newswire ·